Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The potential of interferons in malignant disease.

Literature DB >> 1690107

The potential of interferons in malignant disease.

K Okita¹, T Kaneko.

Abstract

Entities: Disease

Mesh：

Substances：
Interferons

Year: 1990 PMID： 1690107 DOI： 10.2165/00003495-199039010-00001

Source DB: PubMed Journal: Drugs ISSN： 0012-6667 Impact factor: 9.546

Keyword Cloud
References

× No keyword cloud information.

44 in total

1. Virus interference. I. The interferon.

Authors: A ISAACS; J LINDENMANN
Journal: Proc R Soc Lond B Biol Sci Date: 1957-09-12

2. The effects of interferon on the fatty acids in uninfected cells.

Authors: K Apostolov; W Barker
Journal: FEBS Lett Date: 1981-04-20 Impact factor: 4.124

3. Induction of mouse IgG2a- and IgG3-dependent cellular cytotoxicity in human monocytic cells (U937) by immune interferon.

Authors: Y Akiyama; M D Lubeck; Z Steplewski; H Koprowski
Journal: Cancer Res Date: 1984-11 Impact factor: 12.701

4. Phase II study of recombinant alfa-2a interferon in patients with advanced bone sarcomas.

Authors: J H Edmonson; H J Long; S Frytak; W A Smithson; L M Itri
Journal: Cancer Treat Rep Date: 1987 Jul-Aug

5. Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma.

Authors: J R Quesada; A Rios; D Swanson; P Trown; J U Gutterman
Journal: J Clin Oncol Date: 1985-11 Impact factor: 44.544

6. Human leukocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma: a randomized clinical trial from the Myeloma Group of Central Sweden.

Authors: A Ahre; M Björkholm; H Mellstedt; G Brenning; L Engstedt; G Gahrton; H Gyllenhammar; G Holm; B Johansson; M Järnmark
Journal: Cancer Treat Rep Date: 1984-11

The potential of interferons in malignant disease.

1. Virus interference. I. The interferon.

2. The effects of interferon on the fatty acids in uninfected cells.

3. Induction of mouse IgG2a- and IgG3-dependent cellular cytotoxicity in human monocytic cells (U937) by immune interferon.

4. Phase II study of recombinant alfa-2a interferon in patients with advanced bone sarcomas.

5. Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma.

6. Human leukocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma: a randomized clinical trial from the Myeloma Group of Central Sweden.

7. Phase II study of betaseron (beta ser17-interferon) as treatment of advanced malignant melanoma.

8. Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon.

9. Saturation index of blood cell membrane fatty acids before and after IFN treatment in hairy cell leukemia.

10. How does interferon inhibit tumour growth?